Zobrazeno 1 - 10
of 324
pro vyhledávání: '"Santiago, Viteri"'
Autor:
Manon A Simard, Carlos Cabrera-Galvez, Santiago Viteri, Felix Geist, Nadine Reischmann, Michael Zühlsdorf, Niki Karachaliou
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 57, Iss , Pp 101063- (2024)
MET inhibitors have demonstrated efficacy in treating patients with non-small cell lung cancer (NSCLC) harboring METex14 skipping alterations. Advancements in spatial profiling technologies have unveiled the complex dynamics of the tumor microenviron
Externí odkaz:
https://doaj.org/article/3bf51d62f03b48e4a51b131b02e0e59d
Autor:
Ignacio I Wistuba, Amelia Insa, Mariano Provencio, Bartomeu Massutí, Federico Garrido, Edwin R Parra, Delvys Rodriguez-Abreu, Manuel Cobo, Joaquín Casal-Rubio, Ernest Nadal, Javier Martín-López, Diego Megías, Belén Sierra-Rodero, Alberto Cruz-Bermúdez, Alex Martinez-Marti, Isidoro Barneto Aranda, Santiago Viteri, Marta Casarrubios, Cristina Martinez-Toledo, Virginia Calvo, Marta Molina-Alejandre, Francisco Perea, Javier de Castro, Joaquín Mosquera Martínez, Rafael Muñoz-Viana, Natalia Aptsiauri, Francisco Ruiz-Cabello
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 10 (2024)
Background Loss of human leukocyte antigen (HLA) class I expression and loss of heterozygosity (LOH) are common events implicated in the primary resistance of non-small cell lung cancer (NSCLC) to immunotherapy. However, there is no data on periopera
Externí odkaz:
https://doaj.org/article/8c3f29b6cb394ac3ba9e2fc1ab852402
Autor:
Ana Giménez‐Capitán, Estela Sánchez‐Herrero, Lucía Robado de Lope, Andrés Aguilar‐Hernández, Ivana Sullivan, Virginia Calvo, Irene Moya‐Horno, Santiago Viteri, Carlos Cabrera, Cristina Aguado, Noelia Armiger, Joselyn Valarezo, Clara Mayo‐de‐las‐Casas, Noemí Reguart, Rafael Rosell, Mariano Provencio, Atocha Romero, Miguel A. Molina‐Vila
Publikováno v:
Molecular Oncology, Vol 17, Iss 9, Pp 1884-1897 (2023)
ALK, ROS1, and RET fusions and MET∆ex14 variant associate with response to targeted therapies in non‐small‐cell lung cancer (NSCLC). Technologies for fusion testing in tissue must be adapted to liquid biopsies, which are often the only material
Externí odkaz:
https://doaj.org/article/895f32ea609d4f95922800c025292cd9
Autor:
Nicolas Girard, Keunchil Park, Se-Hoon Lee, Santiago Viteri, Claudio A. Schioppa, Joris Diels, Mustafa Oguz, Bernardo H. Rodrigues, Nora Rahhali, Jan Sermon, Francesca Ghilotti, Tracy Li, Meena Thayu, Roland E. Knoblauch, Parthiv Mahadevia, Byoung Chul Cho
Publikováno v:
Cancer Treatment and Research Communications, Vol 40, Iss , Pp 100832- (2024)
Background: Amivantamab, an EGFR-MET bispecific antibody, is the first approved targeted therapy for patients with EGFR Ex20ins NSCLC after prior platinum-based chemotherapy—a population with historically poor outcomes before amivantamab approval.
Externí odkaz:
https://doaj.org/article/b0e636fa219d41078d74b8b155ecc004
Autor:
Ruth Román-Lladó, Cristina Aguado, Núria Jordana-Ariza, Jaume Roca-Arias, Sonia Rodríguez, Erika Aldeguer, Mónica Garzón-Ibañez, Beatriz García-Peláez, Marta Vives-Usano, Ana Giménez-Capitán, Andrés Aguilar, Alejandro Martinez-Bueno, María Gonzalez Cao, Florencia García-Casabal, Santiago Viteri, Clara Mayo de las Casas, Rafael Rosell, Miguel Angel Molina-Vila
Publikováno v:
Journal of Molecular Pathology, Vol 4, Iss 1, Pp 57-68 (2023)
Genetic and drug sensitivity assays on primary cultures are not only of basic but also of translational interest and could eventually aid oncologists in the selection of treatments. However, cancer cells need to be identified and differentiated from
Externí odkaz:
https://doaj.org/article/4aa6f599da1a468abb18119b19ad755f
Autor:
Santiago Viteri, Anna Minchom, Lyudmila Bazhenova, Sai‐Hong Ignatius Ou, Joshua M. Bauml, Scott A. Shell, Michael Schaffer, Junchen Gu, Jennifer B. Rose, Joshua C. Curtin, Parthiv Mahadevia, Nicolas Girard
Publikováno v:
Molecular Oncology, Vol 17, Iss 2, Pp 230-237 (2023)
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) account for ≤ 12% of all EGFR‐mutant nonsmall cell lung cancers. We analysed real‐world datasets to determine the frequency of ex20ins variants, and the ability of po
Externí odkaz:
https://doaj.org/article/c4da93c6b1ad420a85fa00e6dd68825d
Publikováno v:
The Journal of Liquid Biopsy, Vol 1, Iss , Pp 100008- (2023)
To this day, the phase III trial continues to be, as it was more than 60 years ago, the standard for the incorporation of new treatments in oncology. We currently have new tools such as NGS, Liquid Biopsy (LB), Big Data (BD) and Artificial Intelligen
Externí odkaz:
https://doaj.org/article/0eca988e0e7d433fb838abaf6ffc7f3f
Autor:
Magnus Jaderberg, Victor Levitsky, Luis Paz-Ares, Nicolas Isambert, Susana Cedres, Xavier Serres, Charles Ricordel, Sylvia Vetrhus, Alex Martinez-Marti, Santiago Viteri, Alejandro Navarro, Jon Zugazagoitia, Santiago Ponce, Mercedes Herrera-Juarez, Mathieu Lederlin, Thomas Birkballe Hansen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background ONCOS-102, an oncolytic adenovirus expressing granulocyte-macrophage colony-stimulating factor, can alter the tumor microenvironment to an immunostimulatory state. Combining ONCOS-102 with standard-of-care chemotherapy for malignant pleura
Externí odkaz:
https://doaj.org/article/948af889fc44483eac5e19bcc3f77280
Autor:
Niki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, Sara Pilotto, Ana Drozdowskyj, Carles Codony-Servat, Ana Giménez-Capitán, Miguel Angel Molina-Vila, Jordi Bertrán-Alamillo, Radj Gervais, Bartomeu Massuti, Teresa Morán, Margarita Majem, Enriqueta Felip, Enric Carcereny, Rosario García-Campelo, Santiago Viteri, María González-Cao, Daniela Morales-Espinosa, Alberto Verlicchi, Elisabetta Crisetti, Imane Chaib, Mariacarmela Santarpia, José Luis Ramírez, Joaquim Bosch-Barrera, Andrés Felipe Cardona, Filippo de Marinis, Guillermo López-Vivanco, José Miguel Sánchez, Alain Vergnenegre, José Javier Sánchez Hernández, Isabella Sperduti, Emilio Bria, Rafael Rosell
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/907f95952a6f451dab4695071025b8b3
Autor:
Daniel Castellano, Andrea B. Apolo, Camillo Porta, Jaume Capdevila, Santiago Viteri, Cristina Rodriguez-Antona, Lidia Martin, Pablo Maroto
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Cabozantinib monotherapy is approved for the treatment of several types of solid tumors. Investigation into the use of cabozantinib combined with other therapies is increasing. To understand the evidence in this area, we performed a syste
Externí odkaz:
https://doaj.org/article/3a9dbb257b134acc968d6ee7d8d17ca9